Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rallybio Corp.

0.4500
-0.1070-19.21%
Post-market: 0.48000.0300+6.67%19:27 EDT
Volume:183.95K
Turnover:88.32K
Market Cap:18.73M
PE:-0.34
High:0.6325
Open:0.5723
Low:0.4301
Close:0.5570
Loading ...

Company Profile

Company Name:
Rallybio Corp.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
25
Office Location:
234 Church Street,Suite 1020,New Haven,Connecticut,United States
Zip Code:
06510
Fax:
- -
Introduction:
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Directors

Name
Position
Martin Mackay
Chief Executive Officer and Chairman
Helen M. Boudreau
Director
Kush M. Parmar
Director
Lucian Iancovici
Director
Paula Soteropoulos
Director
Rob Hopfner
Director
Ronald M. Hunt
Director
Timothy M. Shannon
Director

Shareholders

Name
Position
Martin Mackay
Chief Executive Officer and Chairman
Stephen Uden
President, Chief Operating Officer and Chief Scientific Officer
Jeffrey M. Fryer
Chief Financial Officer and Treasurer
Steven Ryder
Chief Medical Officer